Solid GHB Formulation for Bioequivalence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Sodium oxybate, used to treat narcolepsy and other conditions, poses challenges due to its high water solubility and hygroscopic nature, making it difficult to formulate into effective solid unit dosage forms that ensure immediate release and bioequivalence with existing oral solutions.
Innovation Solution
Development of immediate release formulations, such as tablets, that incorporate high drug loading with lubricants and minimal excipients, allowing for rapid dissolution and absorption comparable to existing oral solutions, while addressing the challenges of high dose administration and patient convenience.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If sodium oxybate is formulated into solid unit dosage forms with common excipients, then ease of administration and patient convenience are improved, but dissolution performance and bioequivalence with oral solution deteriorate
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by using high drug loading (90-98% w/w sodium oxybate), minimal excipients, specific particle size ranges (10-500 micrometers), and controlled moisture content (0.1-5% w/w) to achieve both ease of administration and rapid dissolution comparable to oral solution
Solution Approach 2:
The patent applies local quality by creating specific formulation zones with different properties: the core contains high concentration of sodium oxybate particles with specific size distribution, while minimal excipients are strategically placed to ensure rapid dissolution without compromising ease of administration
2Ease of operation
If high drug loading is used in solid formulations, then patient compliance and convenience are improved, but formulation stability and handling difficulty increase due to high water solubility and hygroscopic nature
Solution Approach 1:
The patent creates a protected environment by controlling moisture content to 0.1-5% w/w and using desiccants or moisture-barrier coatings to isolate the hygroscopic sodium oxybate from atmospheric moisture, thereby maintaining formulation stability while achieving high drug loading for patient compliance
Solution Approach 2:
The patent employs moisture-barrier coatings or film encapsulation to protect the high drug loading formulation from moisture ingress, preventing degradation while maintaining the convenience of solid unit dosage forms
3Reliability
If large amounts of drug are required to achieve clinical effect, then therapeutic efficacy is improved, but dosage form size and administration complexity increase
Solution Approach 1:
The patent merges multiple doses or high drug loading into a single unit dosage form containing 90-98% w/w sodium oxybate, eliminating the need for complex multi-dose regimens and large-volume liquid administration while maintaining therapeutic efficacy through rapid dissolution
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immediate release formulations achieve bioequivalence with Xyrem® sodium oxybate oral solution, ensuring rapid drug absorption and improved patient compliance through convenient solid dosage forms that maintain therapeutic efficacy.
Implementation Method 1
designed for immediate release of the sodium oxybate into the gastrointestinal tract
Data Source
AI summary
The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.